Phase I and Pharmacokinetic Study of Weekly 5-Fluorouracil Administered with Granulocyte-Macrophage Colony-Stimulating Factor and High-Dose Leucovorin: A Potential Role for Growth Factor as Mucosal Protectant

References

• Gabrilove J. L., Jakubowski A., Scher H., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-ceil carcinoma of the uro-thelium. N Engl J Med 1988; 318: 1414–1422
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Wolf M., Lusk J., et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895
   PubMed Web of Science ®Google Scholar
• Taylor K. M., Jagannath S., Spitzer G., et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in hodgkin's disease. J Clin Oncol 1989; 7: 1791–1799
   PubMed Web of Science ®Google Scholar
• Lieschke G. J., Ramenghi U., O'Connor M. P., et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Hematol 1992; 82: 589–595
   PubMed Web of Science ®Google Scholar
• Crawford J., Glaspy J., Vincent M., et al. Effect of filgrastim (r-met-huG-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide (CAE)). Proc Am Soc Clin Onc 1994; 13: 442, (abstract)
   Google Scholar
• Chevallier B., Chollet P., Merrouche Y., et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564–1571
   PubMed Web of Science ®Google Scholar
• Gordon B., Spadinger A., Hodges E., et al. Effect of granulocytemacrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 1994; 12: 1917–1922
   PubMed Web of Science ®Google Scholar
• Herrmann F., Schulz G., Wieser M., et al. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Amer J Med 1990; 88: 619–624
   PubMed Web of Science ®Google Scholar
• Ho A. D., Del Valle F., Engelhard M., et al. Mitoxantrone/high-dose ara-c and recombinant human GM-CSF in the treatment of refractory non-hodgkin's lymphoma. A pilot study. Cancer 1990; 66: 423–430
   PubMed Web of Science ®Google Scholar
• Welte K., Zeidler C., Reiter A., et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056–1063
   PubMed Web of Science ®Google Scholar
• Berkowitz R. J., Crock J., Strickland R., et al. Oral complications associated with bone marrow transplantation in a pediatric population. Am J Pediatr Hematol/Oncol 1983; 5: 53–57
   PubMedGoogle Scholar
• Meropol N. J., Miller L. L., Korn E. L., et al. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992; 84: 1201–1203
   PubMed Web of Science ®Google Scholar
• Schuchter L. M., Luginbuhl W. E., Meropol N. J. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19: 742–751
   PubMed Web of Science ®Google Scholar
• Buroker T. R., O'Connell M. J., Wieand H. S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14–20
   PubMed Web of Science ®Google Scholar
• Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin-modulated fluourouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 1993; 11: 1879–1887
   PubMed Web of Science ®Google Scholar
• Manual of Oncologic Therapeutics, R. E. Wittes. JB Lippincott Company, Philadelphia 1991; 445–448
   Google Scholar
• Haller D. G., Catalano P. J., MacDonald J. S., et al. Fluorouracil (FU), Leucovorin (LV) and Levamisole (LEV) adjuvant therapy for colon cancer: Preliminary results of INT-0089. Proc Am Soc Clin One 1996; 15: 486, (abstract)
   Google Scholar
• Cao S., Frank C., Shirasaka T., et al. 5-fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1995; 1: 839–845
   PubMed Web of Science ®Google Scholar
• Meropol N. J., Petrelli N. J., Rustum Y. M., et al. A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma. Invest New Drugs 1995; 12: 149–155
   Google Scholar
• Rocci M. L., Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983; 16: 203–216
   PubMedGoogle Scholar
• Trave F., Rustum Y. M., Petrelli N. J., et al. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol 1988; 6: 1184–1191
   PubMed Web of Science ®Google Scholar
• Haller D. G., Lefkopoulou M., MacDonald J. S., . Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the Intergroup colon adjuvant trial (INT-0089). Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation, Y. M. Rustum, et al. Plenum Press, New York 1993; 51–54
   Google Scholar
• Madajewicz S., Pettelli N., Rustum Y. M., et al. Phase I—II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 1984; 44: 4667–4669
   PubMed Web of Science ®Google Scholar
• Grem J. L., McAtee N., Murphy R. F., et al. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994; 12: 560–568
   PubMed Web of Science ®Google Scholar
• Chi K-H., Chen C-H., Chan W-K., et al. Effect of granulocyte-macrophage colony stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorourcil, and leucovorin chemotherapy. J Clin Oncol 1995; 13: 2620–2628
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., Broxmeyer H. E., Hittelman W. N., et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992; 10: 1266–1277
   PubMed Web of Science ®Google Scholar
• Bussolino F., Wang J. M., Defilippi P., et al. Granulocyte- and granu-locyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–473
   PubMed Web of Science ®Google Scholar
• Hancock G. E., Kaplan G., Cohn Z. A. Keratinocyte growth regulation by the products of immune cells. J Exp Med 1988; 168: 1395–1402
   PubMed Web of Science ®Google Scholar
• Lowes J. R., Priddle J. D., Jewell D. P. Production of epithelial cell growth factors by lamina propria mononuclear cells. Gut 1992; 33: 39–43
   PubMed Web of Science ®Google Scholar
• Morrissey P. J., Charrier K., Braddy S., et al. CS4+ T cells that express high levels of cd45rb induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified cd4+ T cells. J Exp Med 1993; 178: 237–244
   PubMed Web of Science ®Google Scholar
• Du X. X., Doerschuk C. M., Orazi A., et al. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994; 83: 33–37
   PubMed Web of Science ®Google Scholar
• Ciacci C., Mahida Y. R., Dignass A., et al. Functional interleukin-2 receptors on intestinal epithelial cells. J Clin Invest 1993; 92: 527–532
   PubMed Web of Science ®Google Scholar